Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …

Health professionals are encouraged to take the Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …

Background GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE)
in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists …

Background Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization for
heart failure in patients with heart failure and a reduced ejection fraction, but their effects in …

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure in patients regardless of the presence or absence of …

Background Trials of statin therapy have had conflicting findings on the risk of development
of diabetes mellitus in patients given statins. We aimed to establish by a meta-analysis of …

Background Overweight and obesity are increasing worldwide. To help assess their
relevance to mortality in different populations we conducted individual-participant data meta …

ESC Guidelines 3039 administrative staff and by the referees and supervisory committees of
the two organizations. It is our hope that this huge effort has generated guidelines that will …

Background—The National Cholesterol Education Program (NCEP) recently proposed a
simple definition for metabolic syndrome. Information on the prospective association of this …

Background Type 2 diabetes is a chronic disorder that requires lifelong treatment. We aimed
to assess whether intensive weight management within routine primary care would achieve …